Lurasidone for schizophrenia: what’s different?

References

• Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med.13(9), 1102–1107 (2007).
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses4(3), 189–200 (2010).
   PubMedGoogle Scholar
• Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia – all roads lead to dopamine. Eur. Neuropsychopharmacol.17(Suppl. 2), S101–S107 (2007).
   Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1253 (2005).
   PubMed Web of Science ®Google Scholar
• Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry45(9), 789–796 (1988).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry163(4), 600–610 (2006).
   PubMed Web of Science ®Google Scholar
• Jones P, Barnes T, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry63(10), 1079–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Davis J, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60(6), 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry70(5), 627–643 (2009).
   PubMed Web of Science ®Google Scholar
• Allison D, Mentore J, Heo M et al. Antipsychotic induced weight gain: a comprehensive literature synthesis. Am J. Psychiatry156(11), 1686–1696 (1999).
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Citrome L. Olanzapine: review of safety 2008. Expert Opin. Drug Saf.7(6), 761–769 (2008).
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev.4, CD006627 (2009).
   Google Scholar
• Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst. Rev.12, CD006629 (2010).
   Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin. Pharmacother. doi:10.1517/14656566.2011.626767 (2011) (Epub ahead of print).
   Google Scholar
• Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence2(4), 261–271 (2008).
   PubMedGoogle Scholar
• Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad. Med.123(2), 153–162 (2011).
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin. Schizophr. Relat. Psychoses4(4), 251–257 (2011).
   PubMedGoogle Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int. J. Clin. Pract.65(2), 189–210 (2011).
   PubMed Web of Science ®Google Scholar
• Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther. Clin. Risk Manag.7, 239–250 (2011).
   PubMed Web of Science ®Google Scholar
• Owen RT. Lurasidone: a new treatment option for schizophrenia. Drugs Today47(11), 807–816 (2011).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry168(9), 957–967 (2011).
   PubMed Web of Science ®Google Scholar
• Potkin S, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr. Res.132(2–3), 101–107 (2011).
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Horisawa T, Tokuda K et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther.334(1), 171–181 (2010).
   PubMed Web of Science ®Google Scholar
• Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin. Drug Metab. Toxicol.7(7), 829–846 (2011).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs18(11), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr. Bull.35(3), 549–562 (2009).
   PubMed Web of Science ®Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr.9(10 Suppl. 11), 6–14 (2004).
   PubMed Web of Science ®Google Scholar
• Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J. Pharmacol. Exp. Ther.338(2), 605–614 (2011).
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology28(3), 519–526 (2003).
   PubMed Web of Science ®Google Scholar
• Preskorn S, Chiu YY, Sarubbi D, Ogasa M, Cucchiaro J, Loebel A. Lurasidone pharmacokinetics: assessment of potential for drug–drug interactions. Neuropsychopharmacology35(Suppl. 1), S395 (2010).
   Google Scholar
• Gandelman K, Alderman JA, Glue P et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J. Clin. Psychiatry70(1), 58–62 (2009).
   PubMed Web of Science ®Google Scholar
• Chiu YY, Preskorn S, Sarubbi D, Cucchiaro J, Loebel A. Effect of food on lurasidone absorption. Presented at: NCDEU Meeting. Boca Raton, FL, USA, 14–17 June 2010.
   Google Scholar
• Guay DR. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. Consult. Pharm.26(8), 579–582 (2011).
   PubMedGoogle Scholar
• Newcomer J, Loebel A, Pikalov A, Sarocco P, Cucchiaro J, Siu C. Impact of lurasidone and olanzapine on Framingham ten-year coronary heart disease risk estimate in schizophrenia. Neuropsychopharmacology35(Suppl. 1), S335–S336 (2010).
   Google Scholar
• Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation97(18), 1837–1847 (1998).
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Pikalov A et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, PEARL 3 trial. Neuropsychopharmacology35(Suppl. 1), S313–S314 (2011).
   Google Scholar
• Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res.127(1–3), 188–194 (2011).
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am. J. Psychiatry168(9), 947–956 (2011).
   PubMed Web of Science ®Google Scholar
• Stahl S, Cucchiaro J, Simonelli D, Loebel A. Long-term safety and tolerability of lurasidone in subjects with schizophrenia: results of a 6-month, open-label study. Neuropsychopharmacology35(Suppl. 1), S316–S317 (2010).
   Google Scholar
• Citrome L, Cucchiaro J, Sarma K et al. Long-term safety and tolerability of lurasidone in schizophrenia or schizoaffective disorder: a 12-month, double-blind, active-controlled study. Presented at: 164th Annual Meeting of the American Psychiatric Association. Honolulu, HI, USA, 14–18 May 2011.
   Google Scholar
• Woodberry KA. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry165(5), 579–587 (2008).
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Goldman RS, Burdick KE et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry64(10), 1115–1122 (2007).
   PubMed Web of Science ®Google Scholar
• Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The novel antipsychotic drug lurasidone enhances NMDA receptor-mediated synaptic responses. Mol. Pharmacol.81(2), 113–119 (2012).
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Javitt DC. N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull.83(3–4), 108–121 (2010).
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Green MF, Kern RS et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry165(2), 203–213 (2008).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am. J. Psychiatry163, 426–432 (2006).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Hsu J, Cucchiaro J et al. Cognitive performance in patients with acute schizophrenia treated with lurasidone: a double blind, placebo controlled trial. Presented at: 164th Annual Meeting of the American Psychiatric Association. Honolulu, HI, USA, 14–18 May 2011.
   Google Scholar
• Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J. Clin. Exp. Neuropsychol.31(7), 848–859 (2009).
   PubMed Web of Science ®Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin. Pharmacother.10(12), 1917–1928 (2009).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Lurasidone (Latuda) for schizophrenia. Med. Lett. Drugs Ther.53(1358), 13–14 (2011).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry70(6), 829–836 (2009).
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology216(4), 451–473 (2011).
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr. Dis. Treat.2(4), 427–443 (2006).
   PubMedGoogle Scholar